Journal

Fraudulent Labels and False Claims: What FDA Enforcement Has Actually Targeted

Enforcement in this category has focused less on manufacturing than on what providers claim their product is.

The claim that draws enforcement

The single most targeted assertion is that a compounded preparation is identical to, or the same as, an approved branded drug. It is not, and the difference is legal rather than semantic.

An approved product has been through premarket review of safety, effectiveness and manufacturing quality. A generic has demonstrated bioequivalence and been approved on that basis, which is why it may be substituted. A compounded preparation has done neither. There is no generic tirzepatide or semaglutide, and a compounded product is not therapeutically equivalent as a matter of law.

So "same as Zepbound" is not marketing enthusiasm. It is a claim about regulatory status that is false, and it is the claim enforcement has focused on.

The salt form issue, which is checkable

Semaglutide sodium and semaglutide acetate are different substances from the semaglutide base in approved products. The FDA has stated they are not appropriate for compounding.

This is unusually verifiable for a patient. Ask which form your prescription uses. A provider that cannot answer, or that answers with a salt form, has told you something specific about what you are receiving.

What else has drawn action

Sterility failures. Recalls tied to sterility lapses at compounding facilities have been recurrent. For a sterile injectable this is the most consequential failure mode.

Impurity allegations. Novo Nordisk litigation has alleged that some compounded semaglutide contained impurities at substantial levels. We report that as what it is — an allegation by a competitor manufacturer in active litigation, contested and not established — because reporting it as a finding would be the same error we are describing.

Dosing errors. The FDA has cited adverse events involving self-administration from multi-dose vials, some requiring hospitalisation. That is a design consequence rather than a compounding failure: moving dose measurement from a manufacturing process to a patient's kitchen introduces error the approved presentations do not have.

How to read a provider's language

Five phrases indicate a compliance posture worth noticing.

• "FDA-approved" applied to a compounded medication or a compounding pharmacy. No such category exists.
• "Generic Zepbound" or "generic Wegovy". Neither exists.
• "Same as" or "identical to" a branded product.
• Trial results — SURMOUNT, STEP, SELECT — quoted for a compounded preparation. Those trials studied approved products at studied doses.
• "FDA-registered" presented as though it means approved. Registration means the agency received the required information, and explicitly does not mean the facility is making approved drugs or is in CGMP compliance.

Why counts should be treated carefully

Figures of roughly 30 warning letters to telehealth firms and 50 or more overall during 2025 come from trade press rather than from the agency's own tally. We hold them as reported rather than verified, with a task to check them against FDA's warning letter database before printing a number as fact.

That distinction matters here more than most places. An article about false claims that repeats an unverified count would be making the error it describes.

What a patient can actually do

1. Ask which pharmacy fills the prescription and check it with the state board.
2. Ask the salt form and the concentration.
3. Search the facility name against FDA warning letters and recall notices — both public.
4. Read the provider's own claims against the five phrases above.
5. Ask for a certificate of analysis matched to your batch number.

Why marketing claims rather than manufacturing draw most enforcement

Manufacturing failures are serious and comparatively rare. Marketing claims are pervasive, cheap to make and directly harmful to the reader's decision-making — a patient who believes they are buying an approved product has been deprived of the information they needed to weigh the choice.

Enforcement follows that logic. The "identical to" claim is the one that converts a compounded preparation into something a consumer thinks they understand.

The multi-dose vial as a labelling issue

The dosing-error problem is partly a labelling one. A vial labelled in milligrams, supplied with a syringe marked in insulin units, and accompanied by instructions that do not state the concentration, is an error waiting for a tired patient at week nine.

Good practice states the concentration in mg/mL, the dose in millilitres for that concentration, and matches the syringe to the calculation. That is a labelling and dispensing standard, not a manufacturing one.

What to keep if something goes wrong

1. The vial and its label, including batch number and beyond-use date.
2. The written instructions you were given.
3. The shipping packaging, especially any temperature indicator.
4. Screenshots of the provider's published claims at the time you purchased — pages change.

Reports go to the prescriber, to the state board of pharmacy, and to FDA MedWatch. All three are worth doing; the boards act on patterns, and a pattern requires reports.

The wider point

None of this establishes that compounded medicine is inherently unsafe. It establishes that a category with lighter premarket oversight relies more heavily on the honesty of its marketing — and that enforcement has found that honesty inconsistent often enough to act repeatedly.

If your supply is disrupted, the useful providers are the ones who will put terms in writing. NexLife publishes pricing and dose coverage openly. See its current plans.

Questions readers actually ask